Abstracts Archive - Page 2040 of 2425 - ACR Meeting Abstracts

Abstract Number: 169 • 2014 ACR/ARHP Annual Meeting
Is Gout a Coronary Heart Disease Risk Equivalent, Similar to Diabetes?
Jasvinder A. Singh¹, Rekha Ramachandaran², Jie Zhang³, Fenglong Xie⁴, Shuo Yang⁵, Huifeng Yun⁶ and Jeffrey R. Curtis², ¹Department of Medicine, University of Alabama, Tuscaloosa, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Ryals Soph Bldg., Rm. 517b, Univ. of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁵Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL
Background/Purpose: Diabetes is a well-recognized risk factor for heart disease, increasing the risk of heart disease by 2-3 fold in many studies. Recent ACC/AHA lipid…
Abstract Number: 168 • 2014 ACR/ARHP Annual Meeting
Positive Association Between Tomato Consumption and Serum Urate: Investigating an Anecdotal Trigger of Gout Flares
Tony R. Merriman¹, Nicola Dalbeth², Peter B. B. Jones³, Lisa K. Stamp⁴, Murray Cadzow⁵, Ruth Topless¹ and Tanya Flynn⁵, ¹Department of Biochemistry, University of Otago, Dunedin, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Medicine, Waikato Clinical School, Waikato Hospital, Hamilton, New Zealand, ⁴Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ⁵University of Otago, Dunedin, New Zealand
Background/Purpose: Gout is characterised by intermittent flares of inflammation in response to monosodium urate crystals in the joints. Gout flares can be triggered by dietary…
Abstract Number: 167 • 2014 ACR/ARHP Annual Meeting
Target Serum Urate: Do Patients Know Their Goal?
Brian W. Coburn¹, Kayli A. Bendlin², Harlan Sayles¹, Kathryn S. Hentzen³, Michaela M. Hrdy³ and Ted R. Mikuls¹, ¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²Pharmacy, Omaha VA Medical Center, Omaha, NE, ³Omaha VA Medical Center, Omaha, NE
Background/Purpose: Treat-to-target approaches are used to achieve therapeutic goals in conditions such as diabetes and rheumatoid arthritis. This strategy has also been widely endorsed in…
Abstract Number: 166 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Gout Attack Recurrence during Urate-Lowering Allopurinol Treatment
Myeong Jae Yoon¹, Ji Ae Yang², Sang Hyun Joo¹, Sang Jin Lee¹, Jin Young Moon¹, Hyun Mi Kwon¹, Dong Jin Ko¹, Yeong Wook Song¹ and Eun Bong Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Background/Purpose Gout is a recurrent inflammatory arthritis caused by crystal deposition of monosodium urate, which can be prevented urate-lowering agents such as allopurinol. However, gout…
Abstract Number: 165 • 2014 ACR/ARHP Annual Meeting
Prevalence of Gout in the Adult Population of France in 2013
Thomas Bardin¹, Pierre Clerson², Stéphane Bouée³, Gerard H. Chales⁴, Michael Doherty⁵, René-Marc Flipo⁶, Charles Lambert⁷, Frédéric Lioté⁸, Thierry Poireaud⁹, Thierry Schaeverbeke¹⁰ and Pascal Richette¹¹, ¹Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ²Orgametrie, Roubaix, France, ³Cemka, Bourg la Reine, France, ⁴Dept of Rheumatology, CHR - Hopital Sud, Rennes, France, ⁵Division of Rheumatology, Orthopedics and Dermatology, University of Nottingham, Nottingham, United Kingdom, ⁶rheumatology, Rene Salengro hospital, Lille, France, ⁷Ipsen, Boulogne Billancourt, France, ⁸Hôpital Lariboisière & University Paris Diderot, Paris, France, ⁹Menarini, Rungis, France, ¹⁰Rheumatology, Bordeaux University Hospital, Bordeaux, France, ¹¹INSERM 1132, Université Paris-Diderot, Hôpital Lariboisière, Paris, France
Background/Purpose The prevalence of gout has been studied in several Western countries by various methods to approach gout diagnosis, and has been estimated to vary…
Abstract Number: 164 • 2014 ACR/ARHP Annual Meeting
Gouty Patients with History of Adverse Reaction to Allopurinol Are Not at Higher Risk of Reaction to Febuxostat
Thomas Bardin¹, René-Marc Flipo², Pascal Richette³ and Pierre Clerson⁴, ¹Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ²rheumatology, Rene Salengro hospital, Lille, France, ³INSERM 1132, Université Paris-Diderot, Hôpital Lariboisière, Paris, France, ⁴Orgametrie, Roubaix, France
Background/Purpose Allopurinol is the standard drug for urate-lowering management of gout. Allopurinol is safe in most patients. The most frequent side effects are minor cutaneous…
Abstract Number: 163 • 2014 ACR/ARHP Annual Meeting
Is the Rate of Skin Reactions to Febuxostat Increased in Patients with a History of Skin Intolerance to Allopurinol? a Retrospective, Hospital-Based Study Involving 101 Patients Consecutively Treated with Allopurinol and Febuxostat
Thomas Bardin¹, Gérard Chales², Tristan Pascart³, René-Marc Flipo⁴, Jean-Claude Roujeau⁵, Aurélie Delayen⁶ and Pierre Clerson⁷, ¹Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ²Dept of Rheumatology, CHR - Hopital Sud, Rennes, France, ³Rheumatology, Saint-Philibert Hospital, LOMME, France, ⁴rheumatology, Rene Salengro hospital, Lille, France, ⁵Dermatology, University Paris Est, Créteil, France, ⁶Orgamétrie biostatistiques, Roubaix, France, ⁷Orgametrie, Roubaix, France
Background/Purpose: Allopurinol can lead to skin toxicity. Minor skin reactions are reported in 2-4% of patients and life threatening severe cutaneous reactions (SCARs) in 0.1-0.4%.…
Abstract Number: 162 • 2014 ACR/ARHP Annual Meeting
Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises
Hugh de Lautour¹, Nicola Dalbeth² and William Taylor³, ¹Rheumatology, Auckland District Health Broad, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Rehabilitation Teaching & Research Unit, University of Otago, Wellington, New Zealand
Background/Purpose There are currently no agreed remission criteria for gout. The aim of this study was to establish consensus for elements of potential remission criteria…
Abstract Number: 161 • 2014 ACR/ARHP Annual Meeting
Ultrasonographic Measurement of Renal and Carotid Artery Resistive Indices and Diastolic Function of the Heart in Gout Patients
Rada Gancheva¹, Atanas Kundurdjiev², Mariana Ivanova¹, Todor Kundurzhiev³, Rasho Rashkov¹ and Zlatimir Kolarov¹, ¹University Hospital "St. Iv. Rilski", Clinic of Rheumatology, Sofia, Bulgaria, ²University Hospital "Alexandrovska", Clinic of Nephrology, Sofia, Bulgaria, ³Medical University, Faculty of Public Health, Sofia, Bulgaria
Background/Purpose Our aim was to assess the impact of gout on kidneys, diastolic function of the heart and carotid arteries. We examined ultrasonographic parameters that…
Abstract Number: 160 • 2014 ACR/ARHP Annual Meeting
All Men with Gout Should be Screened for Erectile Dysfunction
Naomi Schlesinger¹, Diane C. Radvanski² and John Kostis³, ¹Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, ²Department of Medicine, Division of Rheumatology, Robert Wood Johnson Medical School, New Brunswick, NJ, ³Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose Erectile dysfunction (ED) is common in the general population. The likelihood of ED increases progressively with age; however, it is not an inevitable consequence…
Abstract Number: 159 • 2014 ACR/ARHP Annual Meeting
Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant or Unresponsive to non-Steriodal Anti-Inflammatory drugs and/or Colchicine: Safety and Efficacy Results from Long Term Follow-up
Naomi Schlesinger¹, Rieke Alten², Thomas Bardin³, H. Ralph Schumacher Jr.⁴, Mark Bloch⁵, Karine Lheritier⁶, Dominik Richard⁶, Andrea Stancati⁷ and Alexander So⁸, ¹Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, ²Charité University Medicine, Berlin, Germany, ³Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ⁴University of Pennsylvania VA Medical Center, Philadelphia, PA, ⁵Holdsworth House Medical Practice, Sydney, Australia, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Campus Forum 1, Novartis Pharma AG, Basel, Switzerland, ⁸Rheumatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland
Background/Purpose Frequently flaring acute gouty arthritis (GA) patients (pts), in whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective, need effective alternative treatments.1 Canakinumab…
Abstract Number: 157 • 2014 ACR/ARHP Annual Meeting
Can We Diagnose Acute Gout without Joint Aspiration? Results of a Prospective Study of 112 Patients Presenting with Acute Arthritis
Pascal Zufferey, Roxana Valcov, Isabelle Fabreguet, Alexandre Dumusc and Alexander So, DAL, RHU/CHUV, Lausanne, Switzerland
Background/Purpose The gold standard for the diagnosis of acute MSU induced arthritis is crystal identification by microscopy after joint aspiration. Alternative diagnostic tools that have…
Abstract Number: 176 • 2014 ACR/ARHP Annual Meeting
Comparative Cardiovascular (CV) Risk and Outcomes Among Patients with Gout, Osteoarthritis (OA), or Both
Svetlana Krasnokutsky¹, Robert T. Keenan², Laura Schneck¹, Craig Tenner³, Helene Strauss⁴, Daria Crittenden⁵, Aaron Lehmann¹ and Michael H. Pillinger¹, ¹NYU School of Medicine, Division of Rheumatology, New York, NY, ²Rheumatology, Duke University, Durham, NC, ³Medicine, NYU School of Medicine, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵Amgen, Thousand Oaks, CA
Background/Purpose: Gout is associated with increased CV risk, both dependent on, and independent of traditional CV risk factors. Recent studies suggest that OA, traditionally considered non-inflammatory,…
Abstract Number: 174 • 2014 ACR/ARHP Annual Meeting
Long Term Safety and Efficacy of Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Results from a 36 Week Extension Study
P Sunkureddi¹, E Tóth², J. P Brown³, R Moericke⁴, D. Richard⁵, K Lheritier⁵, A Stancati⁵ and A Kivitz⁶, ¹Clear Lake Rheumatology, Nassau Bay, TX, ²Flór Francis Hospital Rheumatology Department, Kistarcsa, Hungary, ³CHU de Québec Research Centre and Laval University, Québec, QC, Canada, ⁴Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Gouty arthritis (GA) patients who experience frequent flares and have comorbidities have limited treatment options. Canakinumab (CAN), a selective, human, anti-interleukin1β monoclonal antibody, has…
Abstract Number: 173 • 2014 ACR/ARHP Annual Meeting
Self-Management Education for Patients with Gout: A Review of Existing Resources
Megan Johnston¹, Gareth Treharne², Peter T. Chapman³ and Lisa K. Stamp⁴, ¹Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Psychology, University of Otago, Dunedin, New Zealand, ³Rheumatology, Immunology & Allergy, Christchurch Hospital, Christchurch, New Zealand, ⁴Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose Inadequate patient self-management education resources may contribute to poor management and outcomes for gout. Patient education resources need to be easy to read and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].